Clinical trial
A Within-subject Device-setting Escalation Early Feasibility Study Evaluating the Safety, Tolerability, and Functionality of 3P-100 in Subjects With PH-ILD
NCT05867914 is registered in ClinicalTrials.gov with Third Pole Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Within-subject Device-setting Escalation Early Feasibility Study Evaluating the Safety, Tolerability, and Functionality of 3P-100 in Subjects With PH-ILD
- Lead sponsor
- Third Pole Therapeutics, Inc.
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- December 4, 2023
- Completion date
- March 29, 2024
- Enrollment
- 5 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.